Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
October 31, 1999
Primary Completion Date
December 31, 2001
Conditions
Leukemia
Interventions
BIOLOGICAL
filgrastim
BIOLOGICAL
oblimersen sodium
DRUG
cytarabine
DRUG
fludarabine phosphate
Trial Locations (1)
43210-1240
Arthur G. James Cancer Hospital - Ohio State University, Columbus
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00004862 - Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter